Data&Samples Catalogue

At INNODIA, we are committed to advancing research and innovation in Type 1 Diabetes (T1D) by providing access to a diverse collection of biological samples.

Our mission is to accelerate scientific breakthroughs by providing access to high-quality samples for researchers, innovators, and stakeholders worldwide. Whether you’re working on groundbreaking treatments or pioneering new diagnostic tools, our curated collection is here to support your journey.

At this moment we are only hosting the samples corresponding to the Natural History dataset from the previous INNODIA IMI project. 

Natural History Samples Catalogue

Definitions: 

ND:  Newly Diagnosed Participants. All ND participants had a baseline assessment within 6 weeks from diagnosis of T1D (based on the ADA criteria [1], defined as the time at which insulin therapy was started).

Following up visit schedule for ND participants:

  • ND Visit 1 : Baseline visit (< 6 weeks from diagnosis)
  • ND Visit 2: 3 months follow up
  • ND Visit 3: 6 months follow up
  • ND Visit 4: 9 months follow up
  • ND Visit 5: 12 months follow-up

UFM: Unaffected family members. Participants who have a first-degree relative with T1D (ND participant). The UFM DNA samples correspond to UFMs who were screened, including not only those who tested positive for autoantibodies but also those who did not.

Following up visit schedule for UFM participants

  • UFM Visit 1: Baseline/Screening visit (visit within 3 months following receipt of their autoantibody test result)
  • UFM Visit 2: 6 months follow up
  • UFM Visit 3: 12 months follow up
  • UFM Visit 4: 18 months follow up
  • UFM Visit 5: 24 months follow up
  • UFM Visit 6: 36 months follow up
  • UFM Visit 7: 48 months follow up

Samples available per visit and sample type:

Newly DiagnosedUnaffected Family Members

  • ND Visit 1: 331 β-cell killing (serum), 267 microRNA (EDTA plasma), 602 DNA (EDTA plasma), 501 Urine, 269 PAXGENE (Whole Blood), 325 Stool

  • ND Visit 2: 499 β-cell killing (serum), 0 microRNA (EDTA plasma), 0 DNA (EDTA plasma), 475 Urine, 0 PAXGENE (Whole Blood), 332 Stool

  • ND Visit 3: 448 β-cell killing (serum), 0 microRNA (EDTA plasma), 0 DNA (EDTA plasma), 435 Urine, 0 PAXGENE (Whole Blood), 293 Stool

  • ND Visit 4: 243 β-cell killing (serum), 152 microRNA (EDTA plasma), 0 DNA (EDTA plasma), 377 Urine, 170 PAXGENE (Whole Blood), 229 Stool

  • ND Visit 5: 215 β-cell killing (serum), 108 microRNA (EDTA plasma), 0 DNA (EDTA plasma), 278 Urine, 259 PAXGENE (Whole Blood), 119 Stool

  • UFM Visit 1: 198 β-cell killing (serum), 116 microRNA (EDTA plasma), 4701 DNA (EDTA plasma), 281 Urine, 191 PAXGENE (Whole Blood), 53 Stool

  • UFM Visit 2: 227 β-cell killing (serum), 0 microRNA (EDTA plasma), 0 DNA (EDTA plasma), 0 Urine, 0 PAXGENE (Whole Blood), 73 Stool

  • UFM Visit 3: 119 β-cell killing (serum), 83 microRNA (EDTA plasma), 0 DNA (EDTA plasma), 190 Urine, 112 PAXGENE (Whole Blood), 53 Stool

  • UFM Visit 4: 147 β-cell killing (serum), 0 microRNA (EDTA plasma), 0 DNA (EDTA plasma), 0 Urine, 0 PAXGENE (Whole Blood), 37 Stool

  • UFM Visit 5: 89 β-cell killing (serum), 47 microRNA (EDTA plasma), 0 DNA (EDTA plasma), 111 Urine, 80 PAXGENE (Whole Blood), 41 Stool

  • UFM Visit 6: 54 β-cell killing (serum), 23 microRNA (EDTA plasma), 0 DNA (EDTA plasma), 65 Urine, 62 PAXGENE (Whole Blood), 41 Stool

  • UFM Visit 7: 30 β-cell killing (serum), 11 microRNA (EDTA plasma), 0 DNA (EDTA plasma), 33 Urine, 33 PAXGENE (Whole Blood), 25 Stool

How to request samples

INNODIA is committed to making its sample collection accessible to researchers while ensuring ethical and responsible use. Follow these simple steps to request access:

  1. Explore – Review the available samples in our catalogue.
  2. Submit a Request – Complete the official Sample Access Request Form with details about your study, sample requirements, intended use, and expected outcomes and compliance measures.
  3. Eligibility - The requests are validated according to the License Agreement.
  4. DAC approval – The request is sent to the Data Access Comittee (DAC) where our panel of experts will evaluate your request based on:
    1.  Alignment with Research Use.
    2. Ethical and legal compliance, adherence to the Informed Consent Forms (ICFs).
    3. Suitability of the requesting party’s research proposal.
    4. Protection of data subjects' rights.
  5. Approval & Agreement – Upon approval, you will receive a Material Transfer Agreement (MTA) outlining the terms of sample usage.
  6. Sample Delivery – Once all requirements are met, samples will be shipped following strict biosafety and compliance protocols.